Literature DB >> 22550162

Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.

Ali McBride1, Scott J Antonia, Eric B Haura, Dawn Goetz.   

Abstract

We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma. The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate. The 24-hour methotrexate level was elevated and he continued to have sustained levels for 18 days. Side effects due to elevated serum methotrexate included seizures, mucositis, acute renal failure, and thrombocytopenia. Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2. The patient's symptoms resolved, and his renal function returned to baseline within 2 months. The patient was able to receive future courses of chemotherapy without methotrexate. Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22550162     DOI: 10.1177/0897190012442717

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  7 in total

1.  Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity.

Authors:  Mohammad A Rattu; Neal Shah; Jessica M Lee; Antony Q Pham; Nino Marzella
Journal:  P T       Date:  2013-12

2.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

3.  Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors.

Authors:  David J Reeves; Elizabeth S Moore; Devon Bascom; Brandon Rensing
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 4.  Preventing and Managing Toxicities of High-Dose Methotrexate.

Authors:  Scott C Howard; John McCormick; Ching-Hon Pui; Randall K Buddington; R Donald Harvey
Journal:  Oncologist       Date:  2016-08-05

5.  LC-MS metabolomics comparisons of cancer cell and macrophage responses to methotrexate and polymer-encapsulated methotrexate.

Authors:  Mohammad Ahmad Al-Natour; Ali Alazzo; Amir M Ghaemmaghami; Dong-Hyun Kim; Cameron Alexander
Journal:  Int J Pharm X       Date:  2019-11-12

Review 6.  Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists.

Authors:  Angel A T Uchiyama; Pedro A I A Silva; Moisés S M Lopes; Cheng T Yen; Eliza D Ricardo; Taciana Mutão; Jefferson R Pimenta; Larissa M Machado; Denis S Shimba; Renata D Peixoto
Journal:  Curr Oncol       Date:  2021-02-03       Impact factor: 3.677

7.  Melatonin Attenuates Methotrexate-Induced Reduction of Antioxidant Activity Related to Decreases of Neurogenesis in Adult Rat Hippocampus and Prefrontal Cortex.

Authors:  Kornrawee Suwannakot; Nataya Sritawan; Salinee Naewla; Anusara Aranarochana; Apiwat Sirichoat; Wanassanun Pannangrong; Peter Wigmore; Jariya Umka Welbat
Journal:  Oxid Med Cell Longev       Date:  2022-07-15       Impact factor: 7.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.